Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

XOMA Corporation (XOMA)

19.78   -0.39 (-1.93%) 09-20 00:46
Open: 20.47 Pre. Close: 20.17
High: 21.14 Low: 19.77
Volume: 106,148 Market Cap: 218M
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 10 full-time employees. The firm focuses on the discovery and development of monoclonal antibody-based therapeutics. The company has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 21.172 - 21.32 21.32 - 21.433
Low: 19.399 - 19.591 19.591 - 19.739
Close: 19.516 - 19.774 19.774 - 19.972

Technical analysis

as of: 2020-09-18 4:37:17 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 25.17     One year: 29.40
Support: Support1: 19.33    Support2: 17.96
Resistance: Resistance1: 21.55    Resistance2: 25.17
Pivot: 19.65
Moving Average: MA(5): 20.45     MA(20): 19.67
MA(100): 20.18     MA(250): 21.56
MACD: MACD(12,26): 0.39     Signal(9): 0.34
Stochastic oscillator: %K(14,3): 61.93     %D(3): 70.62
RSI: RSI(14): 52.79
52-week: High: 28.85  Low: 14.14  Change(%): 3.9
Average Vol(K): 3-Month: 5437  10-Days: 3994

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
XOMA has closed below upper band by 44.9%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 10 Sep 2020
Is XOMA (NASDAQ:XOMA) Using Too Much Debt? - Simply Wall St

Wed, 02 Sep 2020
XOMA to Present at Upcoming Investor Conferences - Yahoo Finance

Mon, 31 Aug 2020
Botulism Illness Market Entry Strategies, Countermeasures, Economic Impact And Quantum Sensors Marketing Channels To 2027 | Microbiotix, XOMA Corporation, Molecular Targeting Technologies, AlphaVax, Morphotek - The Daily Chronicle

Fri, 21 Aug 2020
Biodefense Market Sets the Table for Continued Growth | Cleveland BioLabs, Xoma, Bavarian Nordic - The Daily Chronicle

Thu, 13 Aug 2020
What Type Of Shareholders Make Up XOMA Corporation’s (NASDAQ:XOMA) Share Registry? - Simply Wall St

Thu, 06 Aug 2020
XOMA Reports Second Quarter 2020 Financial Results Nasdaq:XOMA - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 11
Shares Float (M) 6
% Held by Insiders 5.54
% Held by Institutions 59.08
Shares Short (K) 690
Shares Short P. Month (K) 701

Stock Financials

EPS -0.990
EPS Est This Year -2.930
EPS Est Next Year -1.320
Book Value (p.s.) 3.480
Profit Margin -89.63
Operating Margin -85.28
Return on Assets (ttm) -6.8
Return on Equity (ttm) -31.8
Qtrly Rev. Growth -53.8
Gross Profit (p.s.) 1.554
Sales Per Share 0.956
EBITDA (p.s.) -0.812
Qtrly Earnings Growth
Operating Cash Flow (M) -6
Levered Free Cash Flow (M) -17

Stock Valuations

PE Ratio -19.98
PEG Ratio
Price to Book value 5.68
Price to Sales 20.70
Price to Cash Flow -39.63

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.